Open an account

InMed Pharmaceuticals

INM · NASDAQ

$1.44+$0.11 (+8.27%)TodayMarket closed ·
Prev close $1.33

About INM

InMed Pharmaceuticals, Inc. engages in developing small molecule drug candidates targeting the CB1/CB2 receptors. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2001-06-21. The firm develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharma segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is a small molecule drug candidate being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

Employees
0
Headquarters
Vancouver, British Columbia
Listed
Jun 21, 2001
Sector
Health Care
Industry
Pharmaceuticals
Website
inmedpharma.com

INM key statistics

Market cap
7.31M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
37.99K
Volume
125.92K
Open price
$1.34
High today
$1.54
Low today
$1.32
52 Week high
$2.33
52 Week low
$0.575

InMed Pharmaceuticals (INM) at a glance

As of Oct 23, 2026, InMed Pharmaceuticals (INM) shares are priced at $1.44, giving the company a market cap of 7.31M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.32 and $1.54. The current price is 9.1% above the day's low and 6.5% below its high.

Volume so far is 125.92K shares, above the average of 37.99K shares a day.

Over the past year InMed Pharmaceuticals has ranged from $0.575 to $2.33, and now sits 49% of the way up that range.

InMed Pharmaceuticals met or beat analyst EPS estimates in 2 of the last 8 quarters. In Q3 FY25 it reported -$1.94 per share against an estimate of $0.00.

INM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 8 quarters, by 15.1% on average.

  1. Q4 FY21: reported -$205.00 per share against an estimate of -$171.70
  2. Q1 FY22: reported -$125.00 per share against an estimate of -$176.75
  3. Q2 FY22: reported -$155.00 per share against an estimate of -$118.68
  4. Q3 FY22: reported -$125.00 per share against an estimate of -$126.25
  5. Q4 FY22: reported -$280.60 per share against an estimate of -$111.10
  6. Q1 FY24: reported -$0.76 per share against an estimate of $0.00
  7. Q2 FY24: reported -$0.19 per share against an estimate of $0.00
  8. Q3 FY25: reported -$1.94 per share against an estimate of $0.00

INM news

  • Vandana Singh

    InMed Pharmaceuticals Merger Partner Raises $200 Million To Boost Migraine Pipeline

  • Press releasePRNewswire

    Mentari Therapeutics Announces $200 Million Private Placement for Migraine Prevention Pipeline

  • Press releasePRNewswire

    Are ESI, INM, HUN, OLN Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--NIMU, INM, OLN, and HUN

  • Press releasePRNewswire

    Are GBTG, INM, CZR, TMHC Obtaining Fair Deals for their Shareholders?

  • Press releaseNewsfile

    InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

  • Press releasePRNewswire

    Are RAMP, INM, D, NEE Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Merger--RAMP, NEE, D, and INM

Similar companies

Companies in the same industry as InMed Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.